AAM
AVIR icon

Ameraudi Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Ameraudi Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-65,000
Closed -$1.4M – 46
2021
Q2 		$1.4M Buy
+65,000
New +$1.95M 0.6% 34

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameraudi Asset Management's AVIR Position: Q3 2021 in Review

Ameraudi Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q3 2021, closing a stake of 65,000 shares — an estimated $1.4M sold.

Ameraudi Asset Management first reported a position in AVIR in Q2 2021 and held it in 1 quarter. The position peaked at $1.4M in Q2 2021. 142 funds tracked by Wall St. Rank hold AVIR as of Q3 2021.

  • Ameraudi Asset Management reported no remaining Atea Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ameraudi Asset Management sold 65,000 Atea Pharmaceuticals shares in Q3 2021, an estimated $1.4M.
  • Ameraudi Asset Management first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Ameraudi Asset Management's Atea Pharmaceuticals position peaked at $1.4M in Q2 2021.
  • 142 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2021.

Based on Ameraudi Asset Management's 13F filing for Q3 2021, filed 20 Oct 2021.